Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Cash from Operations fell 6051.62% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.2 million, marking a year-over-year decrease of 26396.19%. This contributed to the annual value of -$22.5 million for FY2024, which is 6167.82% up from last year.
  • Latest data reveals that Heron Therapeutics reported Cash from Operations of $1.3 million as of Q3 2025, which was down 6051.62% from -$10.9 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Cash from Operations ranged from a high of $3.4 million in Q3 2024 and a low of -$63.0 million during Q2 2021
  • Its 5-year average for Cash from Operations is -$23.7 million, with a median of -$24.9 million in 2023.
  • Over the last 5 years, Heron Therapeutics' Cash from Operations had its largest YoY gain of 13672.51% in 2024, and its largest YoY loss of 57983.71% in 2024.
  • Over the past 5 years, Heron Therapeutics' Cash from Operations (Quarter) stood at -$45.3 million in 2021, then rose by 17.07% to -$37.5 million in 2022, then skyrocketed by 106.54% to $2.5 million in 2023, then crashed by 579.84% to -$11.8 million in 2024, then soared by 111.3% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, -$10.9 million for Q2 2025, and -$8.9 million during Q1 2025.